To understand the mechanisms underlying the anti-LILRB4 antibody–mediated decrease in tumor growth and increase in survival, we analyzed the effects of anti-LILRB4 monoclonal antibody treatment on both intratumoral myeloid and lymphoid cell populations. Here, LILRB4 is linked to neoplasm.